Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor
Executive Summary
The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call
You may also be interested in...
Erbitux First-Line Studies Face Enrollment Challenges From Avastin
ImClone is moving Erbitux development forward with an eye on enrollment
Erbitux First-Line Studies Face Enrollment Challenges From Avastin
ImClone is moving Erbitux development forward with an eye on enrollment
Bristol/ImClone Erbitux Launched At $600 Per Vial; $2,400 For Initial Dose
Bristol-Myers Squibb/Imclone's oncologic Erbitux launched Feb. 25 at an average wholesale price of $600 per 100 mg of cetuximab